However, the potential benefits of GLP-1RAs and dual GIP/GLP-1 RAs in patients with HFrEF or ASCVD without excess weight/obesity remain unexplored, and further studies are needed to assess their effectiveness. This evidence concerns the gene GIP and atherosclerosis.